High-dose toremifene in advanced renal-cell carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 547-551

  Gershanovich, Michael M ^a   Moiseyenko, Vladimir M ^a   Vorobjev, Andrey V ^a   Käpylä, Hannu ^b   Ellmén, Juha ^b   Anttila, Markku ^b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b ORION CORPORATION   (Finland)

Author keywords

Advanced renal cell carcinoma; Fareston; High dose toremifene

Indexed keywords

ANTIESTROGEN; DRUG METABOLITE; TOREMIFENE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER TOXICITY; MALE; METASTASIS; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; TOREMIFENE; TREATMENT OUTCOME;

EID: 0031034831     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050612     Document Type: Article

References (38)

1. Al-Sarraf M, Eyre H, Bonnet J, Saiki J, Gagliano R, Pugh R, Lehane D, Dixon D, Bottomley R (1981) Study of tamoxifen in metastatic renal cell carcinoma and the influence of certain prognostic factors: a Southwest Oncology Group study. Cancer Treat Rep 65:447
2. Anttila M, Valavaara R, Kivinen S, Mäenpää J (1990) Pharmacokinetics of toremifene. J Steroid Biochem 36:249
3. Anttila M, Laakso S, Nyländen P, Sotaniemi E (1995) Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther 57:628
4. Atzpodien J, Kirchner H, Hänninen EL, Deckert M, Fenner M, Poliwoda H (1993) Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29:6
5. Bishop J, Murray R, Webster L, Pitt P, Stokes K, Fennessy A, Olver I, Leber G (1992) Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 30:174
6. Bloom HJG, Baker WH, Dukes CE, Mitchley BCV (1963) Hormone-dependent tumours of the kidney. I. The oestrogen-induced renal tumor of the Syrian hamster hormone treatment and possible relationship to carcinoma of the kidney in man. Br J Cancer 17:611
7. De Riese W, Goldenberg K, Allhoff E, Stief C, Schlick R, Liedke S, Jonas U (1991) Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence. Int Urol Nephrol 23:13
8. DiSilverio F, Concolino G (1983) Steroid receptors and human renal cell carcinoma. In: Campio L, Robustelli DCG, Taylor RW (eds) Endocrine related tumours, vol 2. Raven, New York, pp 199-209
9. Elias L, Blumenstein BA, Kish J, Flanigan RC, Wade JL, Lowe BA, Goodwin JW, Grawford ED (1996) A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. Cancer 78:1085
10. Fosså SD, Kramar A, Dnoz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy of interferon-alpha. Eur J Cancer 30:1310
11. Frank IN, Graham SD, Nabors WL (1991) Urologic and male genital cancers. In: Holleb AI, Fink DJ, Murphy GP (eds) American Cancer Society textbook of clinical oncology. American Cancer Society, Atlanta, p 273
12. Green MD, Whybourne AM, Taylor IW, Sutherland RL (1981) Effects of antiestrogens on the growth and cell kinetics of cultured human mammary carcinoma cells. In: Sutherland RL, Jordan VC (eds) Non-steroidal antiestrogens. Academic Press, Sidney, pp 397-412
13. Hayes DF, VanZyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13:2556
14. Hirsimäki P, Hirsimäki Y, Nieminen L, Payne BJ (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol 67:49
15. Hrushesky WJ, Murphy CP (1977) Current status of the therapy of advanced renal carcinoma. J Surg Oncol 9:277
16. Kellokumpu-Lehtinen P, Jantunen I, Flander M, Johansson R, Nordman E (1995) Combined interferon and vinblastine treatment in advanced renal cell cancer. Acta Oncol 34:975
17. Kriegmair M, Oberneder R, Hofstetter A (1995) Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45:758
18. Liehr JG, Sirbasku DA, Jurka E, Randerath K, Randerath E (1988) Inhibition of estrogen-induced renal carcinogenesis in male Syrian hamsters by tamoxifen without decrease in DNA adduct levels. Cancer Res 48:779
19. Linehar WM, Shipley WU, Parkinson DR (1993) Cancer of the kidney and ureter. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. Lippincott, Philadelphia, p 1023
20. Miller AB, Hoogstraten B, Staguet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
21. Minasin LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Known SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368
22. Muss HB (1988) The role of biological response modifiers in metastatic renal cell carcinoma. Semin Oncol 15 [Suppl 5]:30
23. Papac RJ, Keohane MF (1993) Hormonal therapy for metastatic renal cell carcinoma: combined androgen and provera followed by high dose tamoxifen. Eur J Cancer 29A:997
24. Pizzocaro G, Piva L, Salvioni R, Di Fronzo G, Ronchi E, Miodini P (1986) Adjuvant medroxyprogesterone acetate and steroid hormone receptors in category M0 renal cell carcinoma. An interim report of a prospective randomized study. J Urol 135:18
25. Popov I, Jelic S, Milanovic N, Kovcin V, Vuletic L (1994) High-dose medroxyprogesterone acetate (MPA) for metastatic renal cell carcinoma (abstract 353). Ann Oncol 5 [Suppl 8]:71
26. Porzolt F, Messerer D, Hauptman R, et al (1988) Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. J Cancer Res Clin Oncol 114:95
27. Possinger K, Wagner H, Mergenthaler HG, Flath B, Beykirch M, Wilmanns W (1994) Nierenzellkarzinome. Inzidenz, Diagnostik und systemische Therapie im fortgeschrittenen Stadium. Munch Med Wochenschr 136/8:32
28. Pyrhönen S (1990) Phase III studies of toremifene in metastatic breast cancer. Breast Cancer Res Treat 16 [Suppl]:41
29. Reddel RR, Murphy LC, Hall RE, Sutherland RL (1985) Differential sensitivity of human breast cancer cell lines to the growth inhibitory effects of tamoxifen. Cancer Res 45:1525
30. Stahl M, Wilke H, Schmoll H-J, Schöber C, Diedrich H, Casper J, Freund M, Poliwoda H (1992) A phase II study of high-dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 3:167
31. Stahl M, Wilke H-J, Seeber S, Schmoll H-J (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin Oncol 19 [Suppl 4]:70
32. Valavaara R (1990) Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 16 [Suppl]:31
33. Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G, et al (1993) Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. J Immunother 13:275
34. Weiselberg L, Budman D, Vinciguerra V, Schulman P, Degnan TJ (1981) Tamoxifen in unresectable hypernephroma. A phase II trial and review of literature. Cancer Clin Trials 4:195
35. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW (1990) Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 25:247
36. Wilke H, Stahl M, Schöber C, Kirchner H, Diedrich H, Freund M, Poliwoda H, Schmoll H-J (1987) Increased response rates in progressive and metastatic renal cell carcinoma using high dose (HD) tamoxifen (abstract). Proceedings, 4th European conference on clinical oncology and cancer nursing. November 1-4, Madrid, p 68
37. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP (1993) The triphenylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315
38. Yagoda A, Petrylak D, Thompson S (1993) Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20:303